Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data

Solid Biosciences Inc SLDB reports 1.5-year functional data and patient-reported outcome measures in the ongoing IGNITE DMD Phase 1/2 trial of SGT-001.
SGT-001 is a novel adeno-associated viral (AAV) vector-mediated gene transfer therapy for Duchenne muscular dystrophy (DMD).
The data will be presented today at the World Muscle Society 2021 Virtual Congress.
The data demonstrated durable expression and function of microdystrophin protein after 12 to 24 months post-dosing.
Related Content: Solid Bio's DMD Gene Therapy Shows Promising Early Data, No New Safety Concerns, But Fails To Cheer Investors.
NSAA scores (measurement of functional motor abilities) showed minimal change compared with baseline and suggested benefit after treatment compared to trajectories typically observed in natural history data.
Natural history analyses suggest that patients would usually exhibit a 4.5-point decline in NSAA over 1.5 years.
In contrast, patients exhibited a mean decrease of 1.7 points from baseline and a mean difference of +2.8 points compared with natural history data.
6-Minute Walk Test (6MWT) distances were maintained 1.5 years post-dosing, while natural history analyses suggested a 63.5-meter decline.
The mean increase in the 6MWT was 15.3 meters compared with baseline, and the mean difference compared with natural history data was +78.8 meters.
The percent predicted FVC (lung function tests) continued to show stability or improvement, while natural history analyses suggest a decline of 7.5%.
Patient-reported outcome measures showed meaningful, sustained improvements at 1.5 years compared with baseline.
No new drug-related safety findings were reported.
Price Action: SLDB stock is up 1% at $3.03 during the market session on the last check Thursday.

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga